BFLY · Butterfly Network, Inc. · Stock research

Current Thesis

The leg on offer is unchanged since June: Butterfly re-rating out of the handheld-ultrasound device category into a licensor of its Ultrasound-on-Chip. The number underwriting it is Q2 2026 Butterfly Embedded revenue of $10.8M, +439% YoY, reported 2026-07-30 by a company whose device line grew 2% in the same quarter.

What advanced since the last update is the price behaviour around the supply, and it went the wrong way. The 2026-08-21 close of $9.55 sat 1.5% under the $9.70 trailing-year closing high set 08-10, and the reasonable read then was that the tape had absorbed more than 4.1 million shares of insider selling inside twelve sessions without breaking. On 2026-08-24 the shares closed $8.95 — a one-session give-back of roughly 6%, with no company disclosure that day. That returns the whole 08-17 → 08-21 recovery, leaves the last close 7.7% below the 08-10 high, and puts price back just above the $8.84 low close of 08-14. RSI(14) is 51.6, down from 65.6 on 08-21.

The fundamental clock is now long. Q2 was reported 07-30; Q3 results fall in late October. Between them the only company-dated items management put on the record are FedRAMP full certification (guided to Q3 2026 on the 07-30 call) and the 2026-10-01 first state Home & Community Care implementation. Everything in between is flow.

Bullish and bearish views on Butterfly Network, Inc.

The model's bull view on Butterfly Network, Inc. (BFLY), in brief: Q2 2026 (2026-07-30): revenue $32.612M, +39% YoY, against $29.360M consensus and above the guided high end; adjusted EPS $(0.01) versus $(0.06) expected. The bear view: The device business is flat. Core POCUS revenue was $21.9M in Q2, +2% YoY, on probe units +23% against a 12% decline in average selling price, attributed on the 07-30 call to iQ+ mix and pricing concessions. Volume is being bought with price. Q3 revenue is guided to $26–30M… Both cases follow in full.

Bull Case

• Q2 2026 (2026-07-30): revenue $32.612M, +39% YoY, against $29.360M consensus and above the guided high end; adjusted EPS $(0.01) versus $(0.06) expected.
• Butterfly Embedded revenue $10.8M, +439% YoY. Software and services revenue of $16.9M exceeded product revenue of $15.7M — the mix crossed over inside a single quarter.
• Gross margin 71.4% against 63.7% a year earlier; adjusted EBITDA loss $1.4M against $6.2M in Q2 2025.
• FY2026 revenue guidance raised 2026-07-30 to $119–123M from $117–121M, against $118.682M consensus; FY adjusted EBITDA loss guided $19–23M.
• Director Louise S. Phanstiel bought 115,200 Class A shares on 2026-08-14 at a weighted average of $8.6763, in trades from $8.49 to $8.865, roughly $999.5K, coded P and stated as not made under a Rule 10b5-1 plan (filed 08-17).
• Eleven Embedded partners stated on the 07-30 call, two added in Q2, behind the up-to-$74M/5-year Midjourney structure filed on Form 8-K 2025-11-17 (40 Ultrasound-on-Chip modules) and the Aleph Neuro brain-imaging agreement of 2026-06-25.
• Dated operating levers from the 07-30 call: FedRAMP full certification tracking to Q3 2026, first state Home & Community Care implementation 2026-10-01 with revenue expected in Q4, Compass AI pipeline up fivefold YoY.

Bear Case

• The device business is flat. Core POCUS revenue was $21.9M in Q2, +2% YoY, on probe units +23% against a 12% decline in average selling price, attributed on the 07-30 call to iQ+ mix and pricing concessions. Volume is being bought with price.
• Q3 revenue is guided to $26–30M against Q2's $32.612M, and the adjusted EBITDA loss to $6–9M against Q2's $1.4M. Management's own guide describes a sequential step down — the shape Embedded milestone recognition produces when a milestone does not land inside the quarter.
• Insider distribution runs to more than 4.1 million shares from one holder in twelve sessions (1,876,292 on 07-31/08-03; 2,297,733 on 08-13/14/17 at $8.6973 to $9.5418), with 2,964,187 Class A still held indirectly through Glenview funds and Longview Investors LLC. The 08-17 filing does not identify the sales as made under a Rule 10b5-1 arrangement, so continuation is discretionary and unscheduled.
• Dr. Erica Schwartz left the board effective 2026-08-05 ahead of taking the CDC directorship, announced by the company 2026-08-11. Inference, not a disclosed consequence: the seat vacated carries federal public-health standing at the same moment the stated near-term Core POCUS lever is FedRAMP certification and Department of Veterans Affairs scale-up.
• Published targets sit mostly below the market. Craig-Hallum maintained Buy at $10 on 2026-08-18; the other dated notes are TD Cowen Buy $6 (2026-06-18) and Lake Street Buy $5.50 (2026-04-30), with William Blair Buy and no target (2026-07-31). A single covering target above the last close is a thin valuation anchor for incremental buyers.
• Cash fell to $124.7M at 2026-06-30 from $150.5M at 2025-12-31 against an FY adjusted EBITDA loss guided to $19–23M.

Setup & Price Structure

• Reference closes: $9.70 on 2026-08-10 (trailing-year closing high), $8.84 on 08-14, $9.55 on 08-21, $8.95 on 2026-08-24. Eleven sessions have passed since the high without a close above it. Three-month price change +97.1%.
• The 08-24 session removed the entire post-Glenview recovery without a headline attached. The prior week's absorption of insider supply now looks like a pause in the distribution rather than demand meeting it — an inference from price, not from any disclosure.
• Structure below: the $8.84 low close of 08-14 is the first marker;
• Crowding observables, stated as observables: short interest displayed at 32.69M shares, 15.24% of float, 3.97 days to cover on the Finviz quote page as of 2026-08-21 (the page does not state the settlement date behind the figure); two Rule 10b5-1 plans active (CEO adopted 2025-12-12, founder adopted 2026-03-13) alongside the discretionary Glenview sales; the 08-03 → 08-10 advance to $9.70 occurred with no company disclosure between 07-30 and 08-11.
• The narrative is maturing. It is no longer new attention — the Midjourney leg dates to 2026-06-18 and the fundamental confirmation to the 07-30 print — but it is still working on the numbers and the stock holds most of a near-double. Flow is moderating: no company news since the 08-11 board release, and the last two directional sessions came without disclosure. What would flip it to saturated is a September of falling short interest with price still unable to reclaim $9.70, plus another discretionary Form 4 into any strength.

Catalyst Calendar (next 30 days)

• ~2026-08-26 (est.) — FINRA publication of the 2026-08-14 short-interest settlement file. First file covering the 08-03 → 08-10 advance to $9.70 and the reversal into the 08-13/08-14 Glenview blocks; quantifies how much of a move made without company disclosure was covering versus new ownership.
• Any date, within two business days of a trade — a further Form 4 from the Glenview funds against the residual 2,964,187 Class A shares. Because the 08-13/14/17 sales were not identified as plan-driven, silence through September is itself evidence the overhang has paused.
• ~2026-09-10 (est.) — FINRA publication of the 2026-08-31 settlement file. Shows whether the short base was cut across the 08-14 → 08-21 recovery or added into it.
• ~2026-09-30 (est.) — FedRAMP full certification, stated on the 2026-07-30 call as expected in Q3 2026. Gates U.S. Department of Veterans Affairs sales at scale, where Butterfly holds provisional authorization; a slip pushes the nearest Core POCUS growth lever into 2027.
• Just beyond the window: 2026-10-01, first state commercial implementation of Home & Community Care for congestive heart failure, with revenue expected in Q4; and ~2026-10-29 (est.), Q3 2026 results.

What Would Change Our Mind

The structural question is whether the late-June breakout base holds now that the price leg has stalled and the fundamental calendar is empty until late October. Before it, losing the 2026-08-14 low close of $8.84 on a weekly close would say the August range failed rather than paused.

On fundamentals, Q3 revenue printing at or under the $26M low end of guidance, or Embedded revenue down sequentially in late October with no new contract named and priced, removes the growth that justified the re-rating. Eleven partners with two of them unnamed is not a number a valuation can be built on.

On supply, another discretionary Form 4 against the residual 2,964,187 Class A shares into any recovery above $9.00 would say the holder is selling strength rather than managing a plan.

What would raise conviction instead: a third Embedded licence disclosed by name with contract economics attached; a second broker publishing a target above the prevailing price after Craig-Hallum's $10 of 2026-08-18; FedRAMP certification landing inside Q3 rather than slipping; or a September with no further Glenview filing and a reclaimed close above $9.70.

Correlation Notes

• The re-rating tracks a private company's regulatory clock. Midjourney Medical's whole-body scanner is pre-FDA with no established reimbursement pathway, and the Apollo chips were guided on the 07-30 call for delivery "late 2027 or early 2028". No listed security prices that outcome, so there is no hedge and no read-through from any comparable tape.
• Revenue now has two halves on different cycles: Core POCUS ($21.9M, +2% YoY in Q2) responds to hospital capital and consumables budgets, while Embedded ($10.8M, +439%) responds to semiconductor licensing milestones. Software and services ($16.9M) passing product ($15.7M) in Q2 means the reported top line will increasingly move with milestone timing rather than with unit shipments.
• Short interest at 15.24% of float on the 2026-08-21 Finviz page places the name in the high-short small-cap cohort, where single sessions are set by positioning. The 08-24 give-back with no news, and the 08-03 → 08-10 advance with no news, are both consistent with that.
• Unprofitable small-cap medtech with $124.7M cash at 06-30 and an FY adjusted EBITDA loss guided to $19–23M carries the standard sensitivity of the cohort to rate and risk-appetite shifts, independent of anything Butterfly discloses.